Integrin receptors are considered to be the key factors in carcinogenesis. αIIbβ3-Integrin (GP
IIb/IIIa) is the main glycoprotein of the surface of platelets, its presence has also been noted on the
certain cancer cell lines. The molecular mechanism of its action in cancer cells remains unknown. This
study presents effects of two αIIbβ3-inhibitors: Abciximab and Eptifibatide on apoptosis, expression of
proline oxidase (POX), signaling molecules ERK 1/2, transcription factor NF-κB and HIF-1α, vascular
endothelial growth factor (VEGF) as well as DNA biosynthesis, collagen biosynthesis and prolidase
activity in MCF-7 breast cancer cells. Both ligands induced apoptosis, however we found significant
differences in molecular mechanism of action between tested αIIbβ3-inhibitors. These differences include expression
of POX, HIF-1α, NF-κB,VEGF and collagen biosynthesis. Eptifibatide presented stronger proapoptotic activity in MCF-7
cells than Abciximab. Results of this study suggest that Eptifibatide may be considered as a novel candidate for development
of new anticancer therapy.
Keywords: αIIbβ3-integrins, αIIbβ3-inhibitors, abciximab, eptifibatide, MCF-7 breast cancer cells, apoptosis.
Rights & PermissionsPrintExport